News summary

NeuroXT earns FDA clearance for AI brain scan analyzer for Alzheimer’s

Source: Longevity Technology • Published: 22 Oct 2026, 10:36

Summarized by Masters of Longevity from Longevity Technology.

NeuroXT’s AI medical imaging tool takes center stage in an article about its regulatory milestone and plans for clinical adoption and commercialization.

NeuroXT earns FDA clearance for AI brain scan analyzer for Alzheimer’s
Key Takeaways
  • The company claims it will advance U.S.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.